NASDAQ (SCMP)
$11.65

0.10 (0.87%)

 
Scroll for more

Investors

 
 

Sucampo Pharmaceuticals, Inc. is a publicly traded, global biopharmaceutical company committed to scientific innovation that improves the lives of patients. By achieving our goal of providing cutting-edge medicines to patients in need around the world, we hope to deliver outstanding value to our shareholders.

LEARN MORE ABOUT OUR LATEST NEWS & PRESS RELEASES

Click here to view our news and press releases.

LEARN MORE ABOUT OUR ANNUAL REPORT VIDEO

Click here to view our 2014 Year of Action video.

LEARN MORE ABOUT OUR COMPANY MANAGEMENT

Click here to view our management team.

 
 
 

Sucampo Pharmaceuticals, Inc. is a publicly traded, global biopharmaceutical company committed to scientific innovation that improves the lives of patients. By achieving our goal of providing cutting-edge medicines to patients in need around the world, we hope to deliver outstanding value to our shareholders.

LEARN MORE ABOUT OUR LATEST NEWS & PRESS RELEASES

Click here to view our news and press releases.

LEARN MORE ABOUT OUR ANNUAL REPORT VIDEO

Click here to view our 2014 Year of Action video.

LEARN MORE ABOUT OUR COMPANY MANAGEMENT

Click here to view our management team.

 
 

Sucampo is headquartered in Rockville, Maryland, USA.
Our shares are traded on the NASDAQ Global Market under the symbol SCMP.

 
 

For investor inquiries please contact:

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs

Email: investor@sucampo.com

Phone: +1-240-223-3718

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.